Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy

Cancer Research

Volumn 71, Issue 18, 2011, Pages 6040-6050

  Anand, Sanjay ^a   Wilson, Clara ^a   Hasan, Tayyaba ^b   Maytin, Edward V ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; CALCIPOTRIOL; CALCITRIOL; CASPASE 8; COLECALCIFEROL; COPROPORPHYRINOGEN OXIDASE; FERROCHELATASE; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; EPITHELIUM TUMOR; LOW DRUG DOSE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

AMINOLEVULINIC ACID; ANIMALS; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CASPASE 8; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; DRUG SYNERGISM; HUMANS; MICE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052791959     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0805     Document Type: Article

References (50)

1. Hasan T, Ortel B, Solban N, Pogue BW. Photodynamic therapy of cancer. In:Kufe D, Bast R, Hait W, Hong WK, Pollock RE, Weichselbaurm RR, et al. , editors. Cancer Medicine, 7th ed. Hamilton, Ontario, Canada: BC Decker, Inc.; 2006. p. 537-48.
2. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508. (Pubitemid 39069400)
3. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-8.
4. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997;79:2282-308.
5. Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:227-32. (Pubitemid 36232321)
6. Piacquadio DJ, Chen DM, Farber HF, Fowler JF Jr, Glazer SD, Goodman JJ, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: Investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004;140:41-6. (Pubitemid 38090269)
7. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004;140:33-40. (Pubitemid 38090268)
8. Soergel P, Wang X, Stepp H, Hertel H, Hillemanns P. Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate. Lasers Surg Med 2008;40:611-5.
9. Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 2011;117:938-47.
10. Kostron H. Photodynamic diagnosis and therapy and the brain. Methods Mol Biol 2010;635:261-80.
11. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias.Neurosurgery 2008;62:564-76.
12. Ortel B, Chen N, Brissette J, Dotto GP, Maytin E, Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer 1998;77:1744-51.
13. Ortel B, Sharlin D, O'Donnell D, Sinha AK, Maytin EV, Hasan T. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer 2002;87:1321-7. (Pubitemid 36009140)
14. Sinha AK, Anand S, Ortel BJ, Chang Y, Mai Z, Hasan T, et al. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br J Cancer 2006;95:485-95. (Pubitemid 44232558)
15. Anand S, Honari G, Hasan T, Elson P, Maytin EV. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 2009;15:3333-43.
16. Friedman SJ, Skehan P. Morphological differentiation of human choriocarcinoma cells induced by methotrexate. Cancer Res 1979;39:1960-7. (Pubitemid 9184984)
17. Hatse S, Naesens L, De Clercq E, Balzarini J. Potent differentiation- inducing properties of the antiretroviral agent 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model. Biochem Pharmacol 1998;56:851-9. (Pubitemid 28458979)
18. Schwartz PM, Barnett SK, Atillasoy ES, Milstone LM. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci U S A 1992;89:594-8.
19. Feldman D, Pike JW, Glorieux FH, editors.Vitamin D. 2nd ed. San Diego, CA: Elsevier Academic Press; 2005. p. 1-1892.
20. Bikle DD., Vitamin D: production, metabolism and mechanisms of action; 2009. [cited 2011 Aug. 30]. Available from: http://www.endotext.org/parathyroid/ parathyroid3/parathyroidframe3.htm.
21. Bikle DD, Ng D, Tu CL, Oda Y, Xie Z. Calcium- and vitamin D-regulated keratinocyte differentiation. Mol Cell Endocrinol 2001;177:161-71. (Pubitemid 32506816)
22. Sato N, Moore BW, Keevey S, Drazba JA, Hasan T, Maytin EV. Vitamin D enhances ALA-induced protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. J Invest Dermatol 2007;127:925-34.
23. Anand S, Chakrabarti E, Kawamura H, Taylor CR, Maytin EV. Ultraviolet light (UVB and UVA) induces the damage-responsive transcription factor CHOP/gadd153 in murine and human epidermis: evidence for a mechanism specific to intact skin. J Invest Dermatol 2005;125:323-33. (Pubitemid 41648167)
24. Pye A, Campbell S, Curnow A. Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. J Cancer Res Clin Oncol 2008;134:841-9.
25. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995;133:282-8.
26. Gibson SL, Cupriks DJ, Havens JJ, Nguyen ML, Hilf R. A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization? Br J Cancer 1998;77:235-42. (Pubitemid 28029540)
27. Gibson SL, Havens JJ, Metz L, Hilf R. Is delta-aminolevulinic acid dehydratase rate limiting in heme biosynthesis following exposure of cells to delta-aminolevulinic acid? Photochem Photobiol 2001;73:312-7.
28. Ickowicz Schwartz D, Gozlan Y, Greenbaum L, Babushkina T, Katcoff DJ, Malik Z. Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. Br J Cancer 2004;90:1833-41. (Pubitemid 38725662)
29. Ohgari Y, Nakayasu Y, Kitajima S, Sawamoto M, Mori H, Shimokawa O, et al. Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin. Biochem Pharmacol 2005;71:42-9. (Pubitemid 41713525)
30. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
31. Szegezdi E, Fitzgerald U, Samali A. Caspase-12 and ER-stress-mediated apoptosis: the story so far. Ann N Y Acad Sci 2003;1010:186-94. (Pubitemid 38264973)
32. Ferrario A, Gomer CJ. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 2006;25:251-9. (Pubitemid 43341245)
33. Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009;129:1100-14.
34. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408.
35. Speirs CK, Hwang M, Kim S, Weier L, Chang S, Varki V, et al. Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res 2011;1:43-61.
36. Furre IE, Shahzidi S, Luksiene Z, Moller MT, Borgen E, Morgan J, et al. Targeting PBR by hexaminolevulinate-mediated photodynamic therapy induces apoptosis through translocation of apoptosis-inducing factor in human leukemia cells. Cancer Res 2005;65:11051-60. (Pubitemid 41713376)
37. Furre IE, Moller MT, Shahzidi S, Nesland JM, Peng Q. Involvement of both caspase-dependent and -independent pathways in apoptotic induction by hexaminolevulinate-mediated photodynamic therapy in human lymphoma cells. Apoptosis 2006;11:2031-42. (Pubitemid 44691585)
38. Chen HM, Liu CM, Yang H, Chou HY, Chiang CP, Kuo MY. 5-Aminolevulinic acid induce apoptosis via NF-kappaB/JNK pathway in human oral cancer Ca9-22 cells. J Oral Pathol Med 2011;40:483-9.
39. Cicarma E, Tuorkey M, Juzeniene A, Ma LW, Moan J. Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells. Br J Dermatol 2009;161:413-8.
40. Bellnier DA. Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha. J Photochem Photobiol B 1991;8:203-10.
41. Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 2003;63:7584-90. (Pubitemid 37466677)
42. Seshadri M, Bellnier DA. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem Photobiol 2009;85:50-6.
43. Lutzow-Holm C, De Angelis P, Grosvik H, Clausen OP. 1,25-Dihydroxyvitamin D3 and the vitamin D analogue KH1060 induce hyperproliferation in normal mouse epidermis. A BrdUrd/DNA flow cytometric study. Exp Dermatol 1993;2:113-20.
44. Gniadecki R, Serup J. Stimulation of epidermal proliferation in mice with 1 alpha, 25-dihydroxyvitamin D3 and receptor-active 20-EPI analogues of 1 alpha, 25-dihydroxyvitamin D3. Biochem Pharmacol 1995;49:621-4.
45. Gniadecki R. Stimulation versus inhibition of keratinocyte growth by 1,25-Dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol 1996;106:510-6. (Pubitemid 26116494)
46. Rashid SF, Mountford JC, Gombart AF, Campbell MJ. 1alpha,25- Dihydroxyvitamin D(3) displays divergent growth effects in both normal and malignant cells. Steroids 2001;66:433-40.
47. Grebenova D, Cajthamlova H, Bartosova J, Marinov J, Klamova H, Fuchs O, et al. Selective destruction of leukaemic cells by photoactivation of 5-aminolaevulinic acid-induced protoporphyrin-IX. J Photochem Photobiol B 1998;47:74-81. (Pubitemid 29060528)
48. West CM, West DC, Kumar S, Moore JV. A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. Int J Radiat Biol 1990;58:145-56. (Pubitemid 20216900)
49. Wyld L, Smith O, Lawry J, Reed MW, Brown NJ. Cell cycle phase influences tumour cell sensitivity to aminolaevulinic acid-induced photodynamic therapy in vitro. Br J Cancer 1998;78:50-5. (Pubitemid 28276769)
50. Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 2004;66:62-6. (Pubitemid 38410681)